Myeloablative allogeneic hematopoietic cell transplantation (allo-HCT) may be considered medically necessary as a treatment of
myelodysplastic syndromes (see Policy Guidelines section) or
myeloproliferative neoplasms (see Policy Guidelines section).
Reduced-intensity conditioning (RIC) allo-HCT may be considered medically necessary as a risk-adapted treatment of
myelodysplastic syndromes or
myeloproliferative neoplasms
in individuals who are at high risk of intolerance of a myeloablative conditioning regimen (see Policy Guidelines section).
Myeloablative allo-HCT or RIC allo-HCT for myelodysplastic syndromes and myeloproliferative neoplasms that do not meet the criteria in the Policy Guidelines section is considered investigational.
